The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts. Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficac... [10961 chars]
2026 Copyright © News-Matic.com. All Rights Reserved
